Q-omics provides the consensus-scored ZNF578 profile across patient tissues and cancer cell-line models. ZNF578 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF578 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF578 RNA expression shows 19,070 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where ZNF578 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF578 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF578 survival associations across molecular data types. ZNF578 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF578 RNA expression–survival associations across cancer types. High ZNF578 expression shows unfavorable associations in LUSC and MESO, but favorable associations in HNSC, BRCA, PAAD and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF578 RNA expression.
This table summarizes ZNF578 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF578. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF578 shows lower tumor expression in KIRC, KICH, BRCA, UCEC and BLCA and higher tumor expression in LIHC. The KIRC box plot shows higher ZNF578 RNA expression in normal versus tumor tissue (log2 FC = −0.258, t-test p < 0.001).
This table shows molecular features associated with ZNF578 in patient tissues and cancer cell lines. In patient samples, ZNF578 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF578 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SOFT_TISSUE.
